ConforMIS (NASDAQ:CFMS)‘s stock had its “buy” rating reiterated by Oppenheimer in a research report issued to clients and investors on Tuesday.

Several other research analysts have also commented on the stock. Zacks Investment Research lowered shares of ConforMIS from a “buy” rating to a “hold” rating in a report on Monday, August 6th. BTIG Research restated a “buy” rating and issued a $3.00 price objective on shares of ConforMIS in a report on Thursday, August 2nd. SunTrust Banks restated a “buy” rating on shares of ConforMIS in a report on Monday, July 16th. Finally, ValuEngine upgraded shares of ConforMIS from a “sell” rating to a “hold” rating in a report on Friday, June 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. ConforMIS currently has an average rating of “Buy” and a consensus target price of $3.25.

NASDAQ:CFMS opened at $1.28 on Tuesday. ConforMIS has a 52 week low of $0.88 and a 52 week high of $4.17. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.77 and a quick ratio of 4.15. The firm has a market cap of $70.12 million, a P/E ratio of -1.03 and a beta of 1.10.

ConforMIS (NASDAQ:CFMS) last posted its quarterly earnings results on Friday, August 3rd. The medical instruments supplier reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.03). ConforMIS had a negative net margin of 64.66% and a negative return on equity of 94.69%. The firm had revenue of $19.10 million for the quarter, compared to the consensus estimate of $19.52 million. equities research analysts expect that ConforMIS will post -0.83 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Archon Capital Management LLC purchased a new stake in shares of ConforMIS in the 1st quarter worth about $4,408,000. Sio Capital Management LLC purchased a new stake in shares of ConforMIS in the 1st quarter worth about $3,191,000. Renaissance Technologies LLC grew its position in shares of ConforMIS by 104.6% in the 2nd quarter. Renaissance Technologies LLC now owns 3,006,900 shares of the medical instruments supplier’s stock worth $3,759,000 after buying an additional 1,537,565 shares during the period. ARK Investment Management LLC grew its position in shares of ConforMIS by 64.7% in the 2nd quarter. ARK Investment Management LLC now owns 1,158,321 shares of the medical instruments supplier’s stock worth $1,448,000 after buying an additional 455,160 shares during the period. Finally, Millennium Management LLC grew its position in shares of ConforMIS by 78.1% in the 2nd quarter. Millennium Management LLC now owns 734,165 shares of the medical instruments supplier’s stock worth $918,000 after buying an additional 321,845 shares during the period. Institutional investors and hedge funds own 40.13% of the company’s stock.

ConforMIS Company Profile

ConforMIS, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.

Featured Story: Trading Strategy Methods for Individual Investors

Analyst Recommendations for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.